• Home
  • »
  • Healthcare Professionals

Healthcare Professionals

Alexion has developed and brought to market two highly innovative, first-in-class therapies for patients with severe, life-threatening rare disease. Soliris is approved in nearly 50 countries for the treatment of PNH and in nearly 40 countries for the treatment of atypical HUS. Strensiq is approved by Health Canada as a first-in-class enzyme replacement therapy for patients with confirmed diagnosis of paediatric-onset hypophosphatasia, under the Notice of Compliance with Conditions (NOC/c) policy, pending the results of trials to verify its clinical benefits. Patients should be advised of the nature of the authorization. Approvals under the NOC/c policy are granted to products that, among other factors, are intended for the treatment of a life-threatening or severely debilitating illness, have promising evidence of clinical effectiveness and an acceptable safety profile, and respond to a serious unmet medical need in Canada.  Under this NOC/c approval, Alexion will complete and submit additional data from existing trials and one additional study with Strensiq. 

For medical information about Soliris or Strensiq, please email: medicalinformation.canada@alexion.com

For general inquiries on Soliris or Strensiq, please email: alexion.canada@alexion.com

Additional resources:

To report an adverse event for Strensiq, please call:  1-844-627-7262 (844-MAP-MAP2)

To report at adverse event for Soliris, please call: 1.888.SOLIRIS (1.888.765.4747)

The information cited on this website is for Canadian audiences only. The medicinal products mentioned here are not approved for sale in all markets worldwide. Moreover, currently registered indications of said products may differ from country to country. Therefore, physicians should always consult local prescribing information. Patients should always consult their physician for information regarding these medicinal products.